ID |
TICKER |
DATE |
Notes To Know |
Time |
Broker Rating |
1 |
UROV |
05/05/2019 |
Urovant Sciences to present theapies at the American Urological Associatiomeeting in Chicago |
2:10 pm ET |
Cowen Outperform $25 PT JPM Overweight $24 PT SuntTrust Buy $23 PT |
2 |
NVS |
05/05/2019 |
Phase 3 commencement of dosing announced April 25, 2018.Data at AAN May 5, 2019, 11:30 AM.Completion 2021. |
|
Credit Suisse Outperform $66 PT Guggenheim Buy $86 PT |
3 |
PGNX |
06/05/2019 |
Phase 2/3 data to be presented at AUA May 6, 2019.Phase 3 data due early 2020. |
|
Needham Buy $10 PT |
4 |
MNOV |
06/05/2019 |
Phase 2b top-line data released October 28, 2017. Primary endpoint met.Additional data to be presented at AAN meeting May 6, 2019 at 2:06 PM ET. |
|
B.Riley Buy $22 PT |
5 |
RARX |
07/05/2019 |
Phase 2 trial met endpoints-December 10, 2018.Data to be presented at AAN May 7, 2019, 11:30 a.m. Phase 3 trial to commence 2H 2019. |
|
Raymond James Outperform $49 PT Stifel Buy $48 PT |
6 |
GWPH |
07/05/2019 |
Phase 2 trial met endpoints-December 10, 2018.Data to be presented at AAN May 7, 2019, 11:30 a.m. Phase 3 trial to commence 2H 2019. |
|
Oppenheimer Perform $162 PT Piper Overweight $185 PT |
7 |
BHVN |
07/05/2019 |
Phase 3 data to be presented at AAN in late-breaker May 7, 2019. |
|
Leerink Outperform $67 PT Oppenheimer Outperform $70 PT Cannaccord Buy $80 PT |
8 |
DRRX |
07/05/2019 |
Phase 2/3 data to be presented at AAN May 7, 2019. 1pm. To report preliminary data from the ongoing DUR-928 alcoholic hepatitis (AH) trial and its earnings after the close |
|
|
9 |
BIIB |
07/05/2019 |
Phase 1/2 data to be presented at AAN in late-breaker May 7, 2019.Phase 3 data due 2H 2020. |
|
Pipper Overweight $280 PT RBC Sector Perform $234 PT Cannaccord Neutral $275 PT |
10 |
OVID |
07/05/2019 |
Phase 1/2 data to be presented at AAN in late-breaker May 7,2019.Phase 3 data due 2H 2020. |
|
Cantor Overweight $7.00 PT Pipper Overweight $14.00PT |
11 |
PTCT |
07/05/2019 |
Phase 2/3 data to be presented at AAN May 7, 2019. 1pm. |
|
Bernstein Outperform $47 PT |
12 |
CATB |
09/05/2019 |
Phase 3 data due 2Q 2020.Phase 1/2 data to be presented at AAN May 9,2019. |
|
|
13 |
QURE |
10/05/2019 |
Phase 2b 26-week follow-up data to be presented at HTRS May 10,2019. |
|
Piper Overweight $80 PT |
14 |
SESN |
13/05/2019 |
PDUFA date for sBLA May 13,2019. |
|
|
15 |
REGN |
13/05/2019 |
PDUFA date for sBLA May 13, 2019. |
|
Jefferies Hold $343 PT |
16 |
AMGN |
15/05/2019 |
Phase 1 data due at ASCO June 3,2019, 9am. |
|
BMO Outperform $229 Jefferies Buy $230 |
17 |
MRTX |
17/05/2019 |
Phase 1/2 update due 2H 2019.On watch for potential impact from release of ASCO abstract for AMGN 510 on May 15,2019. |
|
DA Davidson Neutral $22 |
18 |
ACHN |
17/05/2019 |
Phase 2 interim data due May 17,2019. |
|
Barclays Underweight $2.50 |
19 |
MDCO |
18/05/2019 |
Phase 2 open-label data to be presented at National Lipid Association Scientific Sessions on May 18, 2019. |
|
Goldman Buy $54 |
20 |
BMY |
20/05/2019 |
The FDA determined at that time, that the submission of this new information constituted a major amendment to the Sbla and extended the review. |
|
JPM Overweight $59 PT Barclays Overweight $55 PT |
21 |
ATHX |
20/05/2019 |
Phase 2a data released January 23,2019.Data to be presented at ATS, May 20,2019.Phase 2 ONE-BRIDGE commencement of enrolment announced. |
|
|
22 |
LLY |
20/05/2019 |
Phase 2 data due at DDW meeting 18-21 May,2019 |
|
BMO Capital Outperform $133 PT Edward Jones Buy $116 PT |
23 |
PIRS |
22/05/2019 |
Phase 1 initial data due at ATS meeting May 22,2019 1:30pm. |
|
|
24 |
INCY |
24/05/2019 |
PDUFA date under priority review extended by three months to May 24,2019. |
|
Barclays Equaweight $82PT Stifel Hold $92PT |
25 |
NVS |
24/05/2019 |
PDUFA date under priority review extended by three months to May 24,2019. |
|
Guggenheim Buy $86 PT |
26 |
CNCE |
28/05/2019 |
Phase 1 data to be presented at ASCP May 28-31,2019. |
|
Stifel Buy $18 PT Mizuho Buy $23 PT |